|
Jun 10
|
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royal...
|
|
Dec 5
|
Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities
|
|
Dec 4
|
Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors
|